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Trends in the treatment of orthopaedic prosthetic infections
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The most commonly used therapy for prosthetic joint infection is a two-stage prosthetic exchange separated
by 6 weeks of intravenous antibiotic therapy. This often results in long periods of hospitalization, morbidity,
severe functional impairment and sometimes increased mortality. Therefore novel and challenging thera-
peutic approaches have been attempted, particularly in hip prosthetic infection. This includes, whenever
possible, according to the type of microorganism, antibacterial susceptibility and clinical presentation (includ-
ing age and comorbidities): (i) less aggressive surgical techniques (debridement and prosthesis retention,
or re-implantation with a single-stage exchange arthroplasty); and (ii) antibiotic combinations active against
biofilm-associated bacteria, including rifampicin (particularly with quinolones) with excellent bio-availability
which allow prolonged and efficient oral therapy.
Keywords: total joint infection, exchange prosthesis, one-stage prosthetic reimplantation, two-stage prosthetic
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Introduction
Joint replacement surgery, particularly of the hip and knee, has
become one of the most frequent prosthetic surgeries over the past
decades due to its success in restoring function to disabled arthritic
individuals. It is estimated that more than a million joint replace-
ments are performed each year worldwide. However, these opera-
tions are not without complications, the most frequent being aseptic
loosening. But of greater concern is infection, the second most
frequent complication.1
The treatment of infection following total joint arthroplasty
involves surgery and antimicrobial therapy. Surgical alternatives
include debridement and prosthesis retention; re-implantation with
either a single- or two-stage exchange arthroplasty; arthrodesis (knee);
and excision arthroplasty (shoulder, hip). There are no prospective
trials comparing different combinations of surgical procedures. Anti-
microbial therapy should always be combined with surgery. When
used alone, as with chronic suppressive treatment of infection, anti-
microbial therapy is rarely successful.
The duration of the infection is an important factor in determining
optimal treatment. With an infection of greater than 1 month dura-
tion, it has been postulated that biofilm-associated bacterial disease
has progressed to such a degree that cure with prosthetic retention is
less achievable than with resection.2
As regards surgical procedures, two-stage re-implantation is con-
sidered the standard in the treatment of septic prosthetic joints, but is
expensive, may result in large skeletal defects, long periods of hos-
pitalization, severe functional impairment and occasionally death.
This has stimulated re-visiting other surgical techniques and new
concepts in antimicrobial therapy. The main difficulty in comparing
reported studies in the literature is the wide variability concerning a
number of specific variables, including: the host immune system;3 the
type and route of infection; the surgical procedure; the bacteria cul-
tured; and the antibiotics employed. We will review some of the lead-
ing microbiological and clinical studies published in the last decade
that have led not only to a better understanding of the disease, but also
to novel and more controversial therapeutic approaches.
Surgical therapy: controversy between two-stage and 
one-stage revision
The two-stage re-implantation technique involves removal of the
prosthesis and resection of all infected tissue. The pre-requisites for
this method of treatment include adequate bone stock and minimal
medical co-morbidities to allow for multiple surgical procedures.
However, there are many variables associated with two-stage
exchange protocols. These include: use of antibiotic-loaded cement
in the form of beads or a temporary spacer between the first and
second stage; duration of post-operative antibiotic therapy; timing of
re-implantation; use of allograft bone; and selection of a cemented or
a cementless implant.4 The ideal pause between surgeries is not well
established, but frequently results in considerable economic hardship
and morbidity. The interval usually accepted is a minimum of 6 weeks,
during which antibiotic therapy in prescribed.5 Once this antibiotic
period is completed, and if the results of diagnostic studies indicate
eradication of the infection, a new prosthesis is implanted. The
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decline in the level of C-reactive protein seems to be the best test for
monitoring the effectiveness of antibiotic treatment. The value of
aspiration and culture of the previously infected joint to detect those
patients who remain infected is controversial, but its sensitivity
seems high in the detection of infected protheses.6,7 Whereas a two-
stage approach provides a high success rate (about 95%) for eradication
of the infection, it frequently results in major morbidity due to pro-
longed immobilization of the patient, who is typically elderly.
For these reasons, there is enthusiasm for a one-stage revision. The
one-stage re-implantation technique involves the excision of all pros-
thetic components and infected tissue, and the implantation of new
components during the same operation. It is applied mainly for hip
prostheses. For other prosthetic joints (knee, shoulder, elbow), a two-
stage exchange, with the use of antibiotic-loaded cement, is preferred.
Whereas a one-stage revision procedure appears to be much more
attractive because it allows earlier mobility, it exposes the patient to
the risk that remaining bacteria will lead to re-infection of the newly
implanted prosthesis. This procedure is currently used in many cen-
tres—mostly for hip prosthesis—with good results reported in ∼80%
of patients. The consensus is that a one-stage revision should be used
only if the following specific conditions are met: there is no need for
a bone graft; no fistula is present; the met is not due to difficult-to-
treat bacteria, such as methicillin-resistant Staphylococcus aureus
(MRSA) or Pseudomonas aeruginosa; the debridement is extensive,
such that an independent surgeon arriving mid-operation should not be
able to determine that there was a pre-existing infection; and cement
loaded with a targeted antibiotic will always be used. Commercially
available cement can be obtained for a few antibiotics, usually amino-
glycosides, clindamycin, colistin or erythromycin. Aminoglycosides
are not ideal for infection resulting from MRSA, which are often
resistant to such therapy.8 Many surgeons prepare the cement–
antibiotic mixture during surgery, with local recipes that have not
undergone strict validation.
The microorganism should be cultivated before surgery by biopsy
and/or aspiration cultures so that it may be treated with the appropriate
pre-operative or intra-operative antibiotic regimen (which will
expanded upon in the section ‘Antimicrobial therapy’). The optimal
length of post-operative antibiotic therapy is not known. Controlled
studies are mandatory to address the issue of one-stage versus two-
stage revision, as well as to define the ideal duration of antibiotic
therapy.
Surgical therapy: definitive excision arthroplasty 
(hip) or arthrodesis (knee)
Such techniques have demonstrated moderate success with respect
to pain relief and eradication of infection, but are rarely indicated
because of the poor functional outcome. After the resection, the
patient receives an antibiotic regimen similar to that used for the re-
implantation techniques. The accepted indications for these tech-
niques include: poor quality of bone and soft tissues; highly resistant
organisms; patients unsuitable for more demanding reconstructive
surgery; and failure of exchange arthroplasty
Is ‘conservative’ surgical therapy possible?
The technique of debridement and prosthesis retention involves
debridement of infected tissue, exchange of the polyethylene insert
and large volume (9–12 L) pulsatile irrigation with physiological
serum or antiseptic solution. If necessary, debridement may be
repeated. Whereas such an approach can result in low morbidity with
a high success rate, it requires further study.9–11 The current consensus
is that debridement and retention of the prosthesis is a potentially
successful treatment for early post-operative infection, or late acute
haematogenous staphylococcal or streptococcal infection. However,
success is dependent on surgery being performed in the first few days
or up to 2 weeks after the onset of symptoms, and that in the later onset
cases, the prosthesis had been functioning well.
A recent mathematical model has been performed on the clinical
effectiveness of two different management strategies—prosthesis
removal versus debridement and prosthesis retention—for the
infected, well-fixed, total hip arthroplasty in the elderly.12 This analysis
considered that removal of a stable implant can be a difficult opera-
tion in itself, added to which is the subsequent morbidity of immobili-
zation. Initial debridement and retention, on the other hand, may be
associated with increased patient survival and have a favourable
cost-effectiveness ratio for all patients. Debridement and retention
were shown to increase life expectancy by 2.2–2.6 quality adjusted
life months, and had a favourable cost-effectiveness ratio.
Other surgical alternatives, such as re-implantation with single-
stage exchange, arthrodesis or definitive excision are not evaluated in
this mathematical model.
Antimicrobial therapy
Antimicrobial therapy should be always combined with surgery. The
main difficulty in analysing the efficacy of antibiotic therapy for
treatment of prosthetic joint infections is in knowing exactly what
type of surgical procedure was performed. Another factor is the
heterogeneous nature and small number of cases of prosthetic joint
infection included in antimicrobial therapy studies.
Nevertheless, the addition of rifampicin to antibiotic regimens for
treatment of prosthetic joint infection has been shown to be benefi-
cial, and in addition it is believed that combination therapy is more
effective in preventing the failure of treatment secondary to the
emergence of resistant organisms. Penicillin-susceptible strepto-
coccal prosthetic joint infection treated with prosthesis retention and
intravenous penicillin, or once-daily ceftriaxone followed by oral
amoxicillin–rifampicin, appears to be an effective treatment modality.11
The main advantage of the combination of a quinolone plus rifampicin
is their excellent bioavailability, allowing oral administration, with
serum levels comparable to those obtained during intravenous
therapy. In addition, both drugs display high levels of intracellular
penetration and activity against intracellular Staphylococcus species.
Zimmerli and colleagues13 reported a double-blind, randomized,
controlled clinical trial assessing the role of rifampicin in 33 patients
with staphylococcal infection in a variety of orthopaedic implants,
including eight following arthroplasty. All patients underwent surgical
debridement and were randomized to long-term ciprofloxacin with
or without rifampicin. The combination rifampicin–ciprofloxacin
achieved a cure without removal of the implant (relapse after follow-up
of 35 months: 0% in the ciprofloxacin–rifampicin group versus 42%
in the placebo and ciprofloxacin group). The authors did not explicitly
outline the results for the total arthroplasty group. Nevertheless, these
result are promising for the treatment of patients who are unable to
have extensive surgery.
A different approach has been pursued by others. Drancourt
et al.14 reported on a non-randomized trial comparing a combination
of ofloxacin or fusidic acid and rifampicin in 46 patients with
prosthetic infections caused by staphylococcus. Patients with an
infected hip implant were treated for 6 months, with removal of any
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unstable prosthesis after 5 months treatment. Those with infected
knee prostheses were treated for 9 months, with removal of the knee
prosthesis after 6 months of therapy. Treatment was successful for
11 (55%) of 20 patients treated with rifampicin and fusidic acid and
for 11 (50%) of the 22 treated with rifampicin and ofloxacin.
Unfortunately, the use of quinolones may be limited in the future
as quinolone resistance continues to increase. High doses of oral
co-trimoxazole led to a successful outcome in only six of 12 (50%)
arthroplasty patients; three of the four failures occurred because of
intolerance to the drug.15
Pseudomonas aeruginosa and MRSA prosthetic and bone infection
remain difficult challenges, and two-step exchange revision remains
the rule. Brouqui et al.16 utilized a combination of ceftazidime and
ciprofloxacin, and achieved a cure in nine of nine patients with
P. aeruginosa-infected osteosynthetic material, and four of five
patients with hip and knee prostheses, without removing the
implants. Ariza et al.17 have proposed that most failures in MRSA
prosthetic infections are associated with hetero-resistance to vanco-
mycin. For MRSA following surgery, continuous outpatient per-
fusion of vancomycin with steady-state plasma levels of ∼25 mg/L
for several months, has been used with success.18 Teicoplanin adminis-
tered once daily for very prolonged periods appears also to be
efficacious.19 The duration of antibiotic therapy for the treatment of
prosthetic infections is not clearly defined and ranges from 6 weeks to
6 months, with 6 weeks being the most common.
Chronic suppressive therapy
This method of treatment includes long-term antibiotic therapy
without any adjunctive surgical intervention. Early experience has
led to the universal consensus that antimicrobial therapy alone is
frequently unsuccessful and surgery is necessary in the majority of
cases. In the literature, only successful results are reported and the
number of failures is obviously much higher.
Conclusions and challenges
Success in the treatment of an infected prosthesis demands the best
surgical strategy associated with optimal antibiotic therapy, tailored
to the individual patient. Over the last decade significant progress has
been made in both these areas. More conservative surgical
approaches, such as one stage-revision and debridement without
prosthesis removal, are more frequently utilized. Improved anti-
microbial combinations using optimal pharmacokinetics for pro-
longed periods have led to higher rates of cure. In spite of this,
however, these infections present considerable challenges. Hope-
fully, more targeted therapeutic options will derive from a better
understanding and characterization of the mechanisms of prosthetic
joint infection and microbial pathogenicity. In addition, there is a
need for large-scale multicentre trials and extensive databases that
take into account all the variables involved in such complex infec-
tions, and that lend themselves to rigorous statistical analysis.
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